Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis: A Case-Control Study
- PMID: 39146511
- PMCID: PMC11379435
- DOI: 10.1212/NXI.0000000000200282
Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis: A Case-Control Study
Abstract
Background and objectives: Psychosocial adversity and stress, known to predispose adults to neurodegenerative and inflammatory immune disorders, are widespread among children who experience socioeconomic disadvantage, and the associated neurotoxicity and proinflammatory profile may predispose these children to multiple sclerosis (MS). We sought to determine associations of socioeconomic disadvantage and psychosocial adversity with odds of pediatric-onset MS (POMS), age at POMS onset, and POMS disease activity.
Methods: This case-control study used data collected across 17 sites in the United States by the Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis Study. Cases (n = 381) were youth aged 3-21 years diagnosed with POMS or a clinically isolated demyelinating syndrome indicating high risk of MS. Frequency-matched controls (n = 611) aged 3-21 years were recruited from the same institutions. Prenatal and postnatal adversity and postnatal socioeconomic factors were assessed using retrospective questionnaires and zip code data. The primary outcome was MS diagnosis. Secondary outcomes were age at onset, relapse rate, and Expanded Disability Status Scale (EDSS). Predictors were maternal education, maternal prenatal stress events, child separation from caregivers during infancy and childhood, parental death during childhood, and childhood neighborhood disadvantage.
Results: MS cases (64% female, mean age 15.4 years, SD 2.8) were demographically similar to controls (60% female, mean age 14.9 years, SD 3.9). Cases were less likely to have a mother with a bachelor's degree or higher (OR 0.42, 95% CI 0.22-0.80, p = 0.009) and were more likely to experience childhood neighborhood disadvantage (OR 1.04 for each additional point on the neighborhood socioeconomic disadvantage score, 95% CI 1.00-1.07; p = 0.025). There were no associations of the socioeconomic variables with age at onset, relapse rate, or EDSS, or of prenatal or postnatal adverse events with risk of POMS, age at onset, relapse rate, or EDSS.
Discussion: Low socioeconomic status at the neighborhood level may increase the risk of POMS while high parental education may be protective against POMS. Although we did not find associations of other evaluated prenatal or postnatal adversities with POMS, future research should explore such associations further by assessing a broader range of stressful childhood experiences.
Conflict of interest statement
The authors acknowledge the following potential conflicts of interest: L.B. Krupp: grant funding to institution from the Slomo and Cindy Silvian Foundation, Biogen and Novartis, royalties for the use of the Fatigue Severity Scale, consulting fees from Eisai, Roche, Janssen, Gerson Lehrman, MedScape, NeuroLive, Peer View, Bristol Myers Squibb, and General Dynamics Information, honoraria from At The Limits, Cambridge Medical Technologies, Medergy Marketing, WedMD, and CME Outfitters, payment for expert testimony from MCIC Vermont, travel support from Bristol Myers Squibb, DSMB participation with Biogen and Novartis. L. Charvet: consulting fees from Janssen, YBrain, and Springer Healthcare, stock in Johnson and Johnson. L.A. Benson: grant funding to institution from Genentech-Roche, honoraria from Novartis. M. Candee: honoraria and travel support from American Academy of Pediatrics. T.C. Casper: grant funding to institution from Hoffman La Roche. T. Chitnis: consulting fees from Novartis and Genentech-Roche, DSMB participation with Novartis and committee leadership with National MS Society. J. Graves: grant and clinical trial support from the National MS Society, Race to Erase MS, UCSF CTSI RAP program, Biogen, Octave, and Genentech, personal fees from Novartis, Genentech, Alexion, and Celgene. Mary Rensel: research funding from PPD, Novartis, Biogen, Genentech, Connor B Judge (CBJ) Foundation, patient education funds from Genzyme and CBJ Foundation, consulting fees from Biogen, Genentech, Improve Consulting, Kijia, Novartis, honoraria from Genzyme, Biogen, and Multiple Sclerosis Association of America, DSMB participation with Biogen, and is the Founder of Brain Fresh LLC and Co-Founder of Brain Ops Group. J.W. Rose: grant funding to institution from National Multiple Sclerosis Society. A.T. Waldman: grant funding to institution from Ionis Pharmaceuticals, Genentech-Roche, Travere, Novartis, royalties from UpToDate, consulting fees from bluebirdbio, honoraria from National Society of Genetic Counselors, DSMB participation with SwanBio. B. Weinstock-Guttman: grant funding to institution from Biogen, Novartis, Patient Centered Outcomes Research Institute, Bristol Myers Squibb and EMD Serono, consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, LabCorp, Horizon, and Bayer, honoraria from Biogen. E. Waubant: clinical trial funding from Genentech, Alexion and Biogen, research support from Patient Centered Outcomes Research Institute, Consortium of Multiple Sclerosis Centers and Race to Erase MS, consulting fees from Emerald Pharmaceuticals, honoraria from Yoga Moves MS, Neurology Live, and Advance Curriculum, and travel support from ACTRIMS and ECTRIMS. M.P. Gorman: research funding to institution from Genentech-Roche and Biogen. Go to
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical